Ikarian Capital, LLC Macrogenics Inc Call Options Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $5.11 Million - $11.2 Million	523,500 New	523,500 $7.71 Million
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $2.88 Million - $4.19 Million	146,000 Added 48.67%	446,000 $9.34 Million
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $2.05 Million - $3.56 Million	100,000 Added 50.0%	300,000 $8.06 Million
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $949,499 - $1.66 Million	50,000 Added 33.33%	200,000 $6.37 Million
Q4 2019 Jan 31, 2020	BUY	$7.95 - $12.27 $1.19 Million - $1.84 Million	150,000 New	150,000 $1.63 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.